Pralsetinib
Non-Small-Cell Lung Carcinoma
.svg)
Drug Status
Government Approvals
US(FDA)
WHO Essential Medicine
NO
Known Teratogen
NO
Pharmaceutical Class
Kinase Inhibitor
Controlled Drug Substance
No
Pralsetinib
Summary
Pralsetinib is used to treat specific types of non-small cell lung cancer and thyroid cancer. These cancers should have certain genetic mutations and should have spread to other parts of the body.
Pralsetinib is a kinase inhibitor. It blocks the action of certain proteins involved in the growth and spread of cancer cells. By doing this, it helps slow down or stop the growth of cancer cells.
The usual daily dose of Pralsetinib for adults and children aged 12 years and older is 400 mg. It should be taken orally once daily on an empty stomach, either 2 hours before or 1 hour after a meal.
Common side effects of Pralsetinib include musculoskeletal pain, constipation, diarrhea, fatigue, and high blood pressure. Serious adverse effects can include lung disease, liver toxicity, and bleeding events.
Pralsetinib can cause lung disease, high blood pressure, liver toxicity, bleeding events, and tumor lysis syndrome. It can also harm a fetus if given to a pregnant woman. It's recommended to use effective contraception during treatment and for some time after the last dose. Patients should inform their doctor about all medications they are taking to avoid potential interactions.
Indications and Purpose
How does Pralsetinib work?
Pralsetinib is a kinase inhibitor that blocks the action of certain proteins involved in the growth and spread of cancer cells. By inhibiting these proteins, it helps to slow down or stop the proliferation of cancer cells.
Is Pralsetinib effective?
Pralsetinib has been shown to be effective in treating certain types of non-small cell lung cancer and thyroid cancer with specific genetic mutations. Clinical trials have demonstrated significant overall response rates and duration of response in patients with these conditions.
What is Pralsetinib?
Pralsetinib is used to treat certain types of non-small cell lung cancer and thyroid cancer that have specific genetic mutations. It works by blocking the action of a naturally occurring substance that helps cancer cells multiply, thereby slowing or stopping the growth of cancer cells.
Directions for Use
For how long do I take Pralsetinib?
Pralsetinib is typically used until disease progression or until unacceptable toxicity occurs. The duration of use can vary based on individual response and tolerance to the medication.
How do I take Pralsetinib?
Pralsetinib should be taken orally once daily on an empty stomach, at least 2 hours before or 1 hour after a meal. It is important to take it at the same time every day and to follow any specific dietary instructions provided by your healthcare provider.
How should I store Pralsetinib?
Pralsetinib should be stored at room temperature between 68°F to 77°F (20°C to 25°C) and protected from moisture. Keep it in its original container, tightly closed, and out of reach of children.
What is the usual dose of Pralsetinib?
The usual daily dose of Pralsetinib for adults and children aged 12 years and older is 400 mg taken orally once daily on an empty stomach. It should be taken at least 2 hours before or 1 hour after a meal.
Warnings and Precautions
Can I take Pralsetinib with other prescription drugs?
Pralsetinib can interact with strong or moderate CYP3A inhibitors and inducers, which can affect its effectiveness and safety. Patients should inform their healthcare provider about all medications they are taking to avoid potential interactions.
Can Pralsetinib be taken safely while breastfeeding?
Women are advised not to breastfeed during treatment with Pralsetinib and for 1 week after the last dose due to the potential for serious adverse reactions in breastfed children.
Can Pralsetinib be taken safely while pregnant?
Pralsetinib can cause fetal harm when administered to a pregnant woman. Females of reproductive potential should use effective non-hormonal contraception during treatment and for 2 weeks after the last dose. Males with female partners of reproductive potential should use effective contraception during treatment and for 1 week after the last dose.
Is Pralsetinib safe for the elderly?
No overall differences in safety or effectiveness were observed between elderly patients and younger patients. However, as with any medication, elderly patients should be monitored closely for side effects and their treatment should be tailored to their specific health needs.
Who should avoid taking Pralsetinib?
Important warnings for Pralsetinib include the risk of interstitial lung disease, hypertension, hepatotoxicity, hemorrhagic events, and tumor lysis syndrome. Patients should be monitored for these conditions, and the medication should be adjusted or discontinued if severe side effects occur.
